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Pharmacological prevention and early treatment
of post-traumatic stress disorder and acute stress
disorder: a systematic review and meta-analysis
Laurence Astill Wright 1, Marit Sijbrandij2, Rob Sinnerton 1, Catrin Lewis1, Neil P. Roberts1,3 and Jonathan I. Bisson1
Abstract
Post-traumatic stress disorder (PTSD) is a common mental disorder associated with significant distress and reduced
functioning. Its occurrence after a severe traumatic event and association with characteristic neurobiological changes
make PTSD a good candidate for pharmacological prevention and early treatment. The primary aim for this systematic
review and meta-analysis was to assess whether pharmacological interventions when compared to placebo, or other
pharmacological/psychosocial interventions resulted in a clinically significant reduction or prevention of symptoms,
improved functioning or quality of life, presence of disorder, or adverse effects. A systematic search was undertaken to
identify RCTs, which used early pharmacotherapy (within three months of a traumatic event) to prevent and treat
PTSD and acute stress disorder (ASD) in children and adults. Using Cochrane Collaboration methodology, RCTs were
identified and rated for risk of bias. Available data was pooled to calculate risk ratios (RR) for PTSD prevalence and
standardised mean differences (SMD) for PTSD severity. 19 RCTs met the inclusion criteria; 16 studies with adult
participants and three with children. The methodological quality of most trials was low. Only hydrocortisone in adults
was found to be superior to placebo (3 studies, n= 88, RR: 0.21 (CI 0.05 to 0.89)) although this was in populations with
severe physical illness, raising concerns about generalisability. No significant effects were found for the other
pharmacotherapies investigated (propranolol, oxytocin, gabapentin, fish oil (1470 mg DHA/147 mg EPA), fish oil
(224 mg DHA/22.4 mg EPA), dexamethasone, escitalopram, imipramine and chloral hydrate). Hydrocortisone shows
the most promise, of pharmacotherapies subjected to RCTs, as an emerging intervention in the prevention of PTSD
within three months after trauma and should be a target for further investigation. The limited evidence for
hydrocortisone and its adverse effects mean it cannot be recommended for routine use, but, it could be considered as
a preventative intervention for people with severe physical illness or injury, shortly after a traumatic event, as long as
there are no contraindications. More research is needed using larger, high quality RCTs to establish the most
efficacious use of hydrocortisone in different populations and optimal dosing, dosing window and route. There is
currently a lack of evidence to suggest that other pharmacological agents are likely to be effective.
Introduction
Post-traumatic stress disorder (PTSD) is a common
mental disorder manifesting through symptoms of re-
experiencing, hyper-arousal and avoidance following a
traumatic event. In high-risk populations the prevalence
of PTSD is estimated at 15.4%1. PTSD is associated with
substantial physical and psychiatric co-morbidity,
including substance abuse and suicide2. The DSM-5 states
that symptoms must be present for one month following
the traumatic event for PTSD to be diagnosed3. Acute
stress disorder (ASD) has similar symptoms to PTSD, is
diagnosed 3 days to 1 month post-trauma and is a good
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predictor of PTSD4. Therapies to prevent early traumatic
stress reactions developing into chronic PTSD, particu-
larly in high-risk individuals, are needed to alleviate this
significant morbidity.
While some psychological interventions to prevent the
development of PTSD are ineffective5 and others, such as
psychological debriefing after trauma may even be
harmful6, there is evidence of benefit of trauma-focused
cognitive behavioural therapy in treating individuals with
acute traumatic stress symptoms7 and preliminary work
on prolonged exposure therapy in the immediate after-
math of trauma, has shown promise in the reduction of
post-traumatic stress reactions8. The limited evidence
available for treatments incorporating both psychological
and pharmacological intervention, however, has so far
failed to show significant benefit9.
As our scientific understanding of the neurobiological
changes occurring during PTSD onset has increased, more
research has focused on pharmacological interventions to
prevent PTSD. For example, the finding that memory
consolidation appears particularly vulnerable to disruption
in the six hours after trauma10, makes the shifts in neuro-
biological activity in these “golden hours”11 and beyond a
promising target for pharmacological intervention12.
Early research explored the effects of benzodiazepine
administration and was largely ineffective13. Later research
has focused on B-blockers, such as propranolol, and their
ability to disrupt post-synaptic norepinephrine receptors14.
Studies have suggested that human participants who
received propranolol have decreased recall of emotionally
stimulating material, possibly due to the blocking of
memory consolidation15 and subsequent studies have
explored the efficacy of propranolol as a preventive agent16.
Other studies have found an association between low
cortisol levels following motor vehicle accidents and
subsequent PTSD17,18. Both human and animal studies
suggest that glucocorticoids attenuate heightened fear
response19 through increased removal of fear inducing
memories20 resulting in interest in the potential pre-
ventive effects of hydrocortisone.
In addition to propranolol and hydrocortisone, obser-
vational studies have associated early morphine use with
reduced rates of PTSD21 and other drugs, including
SSRIs22, gabapentin23, α-omega fatty acids24 and keta-
mine25 have also been investigated for the prevention of
PTSD. Previous systematic reviews in this area have
highlighted both the sparsity and the poor quality of the
trials24,26. Sijbrandij et al.26 included randomised con-
trolled trials (RCTs), controlled clinical trials and cohort
studies to maximise the number of included studies. After
the meta-analyses of Sijbrandij et al.26 and Amos et al.24
more recent studies have been published, such as a study
on escitalopram22 and a study on oxytocin27. In order to
determine if the evidence has developed in the last few
years, we undertook a further systematic review and meta-
analysis, building on the original review of Sijbrandij
et al.26 but only including RCTs. The inclusion of just
RCTs allowed us to focus on a higher quality of evidence
to offer sound recommendations for future research.
Another difference is that we included studies which
administered the intervention within the first three
months instead of just one month of the trauma. The
study was conducted to update the International Society
of Traumatic Stress Studies 2018 Treatment Guidelines28,
the scoping question for which investigated early phar-
macological intervention within three months of the
traumatic event.
Thus the primary aim for this systematic review and
meta-analysis was to assess whether pharmacological
interventions when compared to placebo, or other phar-
macological/psychosocial interventions resulted in a
clinically significant reduction or prevention of symptoms,
improved functioning or quality of life, presence of dis-
order, or adverse effects. We sought to analyse different
classes of pharmacological agents separately, rather than
pooling the data.
Methods
We adopted a methodology based on the Cochrane
Handbook for Systematic Reviews of Interventions29 and
a PRISMA checklist was completed.
Selection criteria
The inclusion criteria were: (a) any RCT (including
cluster and cross-over trials); (b) investigating the effects
of pharmacological intervention delivered within three
months of the traumatic event; (c) when compared to
placebo, pharmacological or psychosocial interventions;
(d) in participants exposed to a traumatic event likely to
meet the A criterion for DSM5 PTSD; and (e) PTSD or
ASD symptoms measured using one or more validated
clinician administered or self-report outcome measures.
There was no restriction on the severity of PTSD/ASD
symptoms or the type of traumatic event, no restriction
on sample size, and both published and unpublished
studies were eligible for inclusion. Only studies published
in English were included.
Search strategy and selection criteria
For this review we combined an updated search
undertaken by the Cochrane Collaboration with the ori-
ginal search strategy from the review of Sijbrandij et al.26.
This systematic review was undertaken alongside a
number of other reviews carried out to update the ISTSS
Treatment Guidelines28. As part of this all RCTs related
to the prevention and treatment of PTSD from 2013 to
the 31st May 2018 were identified and scrutinised, pro-
ducing 16 new papers on early pharmacotherapy
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considered in more detail here. For this updated search
the inclusion criteria were reconsidered and subsequently
much broader. The time frame for intervention was
extended to 3 months post-trauma. The original search
strategy used PubMed, PsycINFO, Embase and the
Cochrane database of randomised trials with no limitation
on start date. Terms referring to PTSD were combined
with terms referring to pharmacotherapy (using both
MeSH terms and text words) and we also checked the
references of four narrative reviews of pharmacological
prevention of PTSD5,12,16,30. Details of the searches and
exact search strings are provided in the appendix.
All titles and abstracts were appraised by two inde-
pendent screeners and any disagreements were discussed.
The full text of any potentially relevant papers was
acquired and if we were unable to locate the full text for
any study the corresponding author was contacted to
request the paper. To determine if potentially relevant
studies met the inclusion criteria the full text was inde-
pendently reviewed by two authors (L.A.W. and J.I.B.).
Data extraction
Data were extracted by two independent reviewers (L.A.
W. and J.I.B.) using identical data extraction forms. There
were only minor irregularities between reviewers, which
were discussed and consensus agreed on. Study authors
were contacted if more information was required. Basic
demographic data and details of the intervention used was
collected along with primary outcomes of PTSD/ASD
symptom severity and incidence.
Assessment of study bias
The Cochrane Collaboration’s tool for assessing risk of
bias in randomised trials’31 was used for each identified
study. This tool assesses the likelihood of bias in rando-
mised trials, including the adequate generation of alloca-
tion sequence, acceptable concealment of allocation,
satisfactory blinding of participants and personnel, and
assessing the degree of incomplete outcome data. Risk of
bias was assessed by two independent reviewers (L.A.W.
and J.I.B.) and any disagreement resolved by discussion.
These ratings were considered and a GRADE judgement
(which assesses quality of evidence to make recommen-
dations for clinical practice32) was presented for each
outcome.
Synthesis of results
The primary outcome in the meta-analysis was reduction
in PTSD symptoms 3–6 months after the traumatic event
(but it was agreed a priori that the nearest time point to this
would be accepted, and if there was no measure of PTSD
symptoms, ASD symptoms would be included instead).
This was performed using a random-effects model. PTSD
incidence at 3–6 months after the traumatic event was also
considered. For PTSD/ASD incidence we calculated risk
ratios whereas for severity we calculated standardised mean
differences, along with associated confidence intervals. For
outcomes including more than one study we measured
statistical heterogeneity by calculating the I2 statistic (t). As
this was low for all results it did not change our analyses.
Data was pooled if outcomes included two or more studies.
Sub-group analyses were not performed as there were few
studies for individual outcomes. All analyses were done
using the Cochrane Collaboration’s Review Manager
5.3 software33.
Results
The initial search produced 2139 papers. The updated
search was broader and contained 5500 additional papers.
We examined the full text of 111 papers and 18 of these
met the inclusion criteria. One other text which met the
inclusion criteria was highlighted during peer review34.
The other 93 were excluded as per Fig. 1.
Our systematic review identified 19 RCTs with a total of
3629 participants. There were 16 adult RCTs16,20,23,27,34–45
(n= 3387) and three child RCTs46–48 (n= 242). 16 trials
were included in the meta-analysis, with three exclu-
ded39,41,44 as they lacked sufficient information to include.
For example, Schelling et al.41 only included the median
scores (with IQR) for PTSD severity. Tables 1 and 2 show
detailed characteristics of these trials. All studies focused on
early intervention to prevent PTSD/ASD apart from Shalev
et al.36 and Suliman et al.22 which were early treatment
trials. Interventions were classified as early treatment trials
if the intervention extended beyond the first month post-
trauma. Shalev et al.42 initiated treatment with only those
participants who met DSM-IV PTSD diagnostic criteria
(assessed at a mean of 19.8 days post-trauma). Similarly,
Suliman et al.22 included participants meeting the DSM IV
criteria for full or partial ASD, initiating treatment within
28 days. When measuring outcomes from all trials, a clin-
ician administered measure was used where available and
self-report questionnaires if not36,41,43.
Seventeen studies compared effectiveness on PTSD
outcomes, two studies on ASD severity23,47. Robert
et al.47 assessed ASD severity after administering imi-
pramine to one group, and chloral hydrate to another, the
participants were between 5 days and 148 days (mean:
36 days) post-trauma (thermal injury). Robert et al.47
justified their use of ASD by arguing that acute hospita-
lisation for burns is continuously traumatising, and that
the traumatic event continued until discharge. This is,
however, debatable and at odds with commonly accepted
definitions; PTSD would likely have been a more appro-
priate primary outcome to have measured. Stein et al.23
compared both ASD and PTSD outcomes, finding no
significant difference across the three groups—propra-
nolol, gabapentin and placebo.
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Risk of bias assessments
The quality of the RCTs was highly variable and the
majority of the studies had areas of significant risk of bias
in their methodology (explored in Supplementary Table 1
and Supplementary Table 2). Only four studies27,34,38,39
used intention-to-treat (ITT) analysis with the other
15 studies using completer-only analysis (Suliman et al.22
used a modified ITT analysis, with only completer-only
analysis reported and, therefore, used in this meta-analysis
and so it is not considered a true ITT trial).
Meta-analyses
The results of our meta-analyses are shown in Tables 3
and 4. Rosenberg et al.48 and Sharp et al.49 used the same
data set with different follow up periods, because of this
we included the Rosenberg et al. study48 which used
PTSD outcomes. Sharp et al.49 used ASD outcomes and
also noted no significant difference between control and
treatment groups.
A small positive effect was found for hydrocortisone
over placebo on PTSD severity. A larger, but still modest,
effect was found for hydrocortisone over placebo on
PTSD incidence. The forest plots demonstrating these
outcomes are shown in Supplementary Figs. 1 and 2.
Discussion
This systematic review identified 19 RCTs with 16
included in the meta-analysis and found some evidence
for the potential efficacy of hydrocortisone in the pre-
vention of PTSD in adults. There was no evidence to
support the efficacy of propranolol in terms of prevention
of PTSD or ASD. Considering the paucity of evidence
available, it remains difficult to draw firm conclusions on
other agents, although no RCT was able to demonstrate
an overall beneficial effect without sub-group analysis.
Our results mirror those of previous systematic
reviews24,26. Sijbrandij et al.26 identified 15 studies and
evaluated 10 pharmacotherapies while we evaluated 19
and nine respectively. We were unable to evaluate mor-
phine, for which observational studies have associated
morphine administration with a decreased PTSD inci-
dence21, as there were no RCTs but were able to assess
oxytocin, fish oil (1,470 mg DHA/147mg EPA) and fish
oil (224 mg DHA/22.4 mg EPA) due to new evidence.
Amos et al. evaluated four hydrocortisone trials, while
Sijbrandij et al.26 assessed five, and we included
six11,35,36,40,41,43 (with three in the meta-analysis11,35,43).
This accumulation of evidence shows continuing interest
in evaluating hydrocortisone.
Fig. 1 PRISMA flow diagram.
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Initiating a therapy within the first six hours post-trauma
is thought to be crucial to impeding the disruption to
memory consolidation that occurs within this period. Ten
studies initiated therapy within 12 h16,34–37,40,41,43,44,46—
three of propranolol16,37,46, six of hydro-
cortisone35,36,40,41,43,44, one of dexamethasone34. Five of
these hydrocortisone trials36,40,41,43,44 initiated therapy
within the “golden” six hours, while Delahanty et al.35
administered hydrocortisone within a 12-h window and
their results suggest that hydrocortisone may still be
effective in preventing PTSD outside of a 6-h window.
Only one propranolol trial initiated pharmacotherapy
within 6 h16 and similarly to those initiating therapy later
on, also failed to show a preventative effect on PTSD. It
remains possible, however, that earlier administration may
be more effective in blocking memory consolidation,
although the efficacy of hydrocortisone administration at
beyond 6 h appears to contradict this, in addition to a
limited theoretical basis. It is also likely that memory
consolidation is not the only neurobiological process
causing PTSD and pharmacological agents may act via
different mechanisms or more than one mechanism,
oxytocin for example is an anxiolytic in addition to pos-
sibly affecting memory consolidation27. Disruption of
other causative pathways may produce new avenues for
pharmacological prevention.
Pragmatically, it is difficult to identify, consent and
enrol a participant into a RCT within 6 h of an unexpected
trauma, with many studies thus investigating expected
trauma (e.g., Intensive Therapy Unit (ITU) admission,
cardiac surgery). Hydrocortisone remains a potentially
promising intervention for PTSD and is particularly well
suited to trauma that necessitates prompt presentation to
a hospital setting such as severe injury. Furthermore there
is scope for large scale administration in a low resource
setting, given its widespread availability as an WHO
essential medicine50 and its low cost. Given this, it may be
better suited to a low resource or disaster setting than a
more complicated psychosocial intervention. The possible
necessity to administer it within a six-hour time window
would hamper its use following many traumatic events
and it is only likely to be of pragmatic use if future
research confirms it is effective beyond the “golden
hours”.
Given the physical conditions of participants and acute
hospital settings of the hydrocortisone trials to date,
generalisability to other trauma populations is limited and
it is possible that co-prescription of other drugs may have
subjected the results to confounding. For example, ino-
tropes like noradrenaline are frequently used in septic
ITU patients40 and correlations have been found between
chronic PTSD and raised urinary noradrenaline excre-
tion51. It may be that noradrenaline tempers the effect of
hydrocortisone and without endogenous noradrenaline
administration hydrocortisone may have a greater effect.
Furthermore, dosing varied, from 20mg BD PO hydro-
cortisone35 to a 100mg IV bolus, followed by a con-
tinuous infusion with subsequent tapering43. Delahanty
et al.’s35 work suggested efficacy with an oral formulation,
which if validated by subsequent research could increase
the usability of hydrocortisone beyond secondary care and
into low resource settings.
The analysis of escitalopram, gabapentin, oxytocin, fish
oil (1470mg DHA/147mg EPA) and fish oil (224 mg
DHA/22.4 mg EPA) was limited by the paucity of studies.
Only escitalopram was assessed by more than one study.
None of these studies administered the treatment within
6 h, and the two escitalopram studies were early treat-
ment, not prevention, studies. It remains possible that
earlier administration could be beneficial in preventing
PTSD/ASD. Furthermore, the two fish oil studies used
vastly different dosages, with neither showing a pre-
ventative effect.
Many of the studies examined also investigated
concurrent psychiatric co-morbidity. Twelve investi-
gated coexisting depressive symptom sever-
ity22,23,27,34,35,37,38,43–46,48, but the only significant
differences observed between control group and
intervention were in those studies investigating
hydrocortisone. Hydrocortisone groups reported sig-
nificantly less depressive symptoms in two studies—
Delahanty et al.35 and Zohar et al.44. Zohar et al.44 also
found fewer anxiety symptoms in the hydrocortisone
group, while Delahanty et al.35 found improvements in
health related quality of life (HRQL) measures in the
intervention group. Likewise, Weis et al.43 noted
improvements in HRQL. It is possible that hydro-
cortisone administration may reduce secondary
Table 4 Effects of pharmacotherapy for PTSD prevention in child and adolescent participant RCTs.
Pharmacotherapy Outcome Comparisons Participants (n) RR/SMD (95% CI) I2 GRADE judgement
Propranolol PTSD severity 1–3 months 1 20 SMD: 0.01 (−0.87 to 0.89) NA Very low
Propranolol PTSD 1 month–7 years 2 217 RR: 0.48 (0.13 to 1.77) NA Very low
Imipramine (vs. chloral hydrate) ASD severity 0–7 days 1 25 RR: 2.17 (1.04 to 4.51) NA Very low
PTSD, post-traumatic stress disorder, ASD, acute stress disorder, n, number of participants included at final assessment, RR, relative risk,
SMD, standard mean difference, CI, confidence interval, NA, not applicable
Astill Wright et al. Translational Psychiatry           (2019) 9:334 Page 7 of 10
depressive symptoms indirectly by mediating the
development of PTSD in traumatised individuals. It is
also possible that attenuating the heightened fear
response with hydrocortisone may prevent the formation
of depression directly, in addition to PTSD. Regardless,
both the amelioration of PTSD and depressive symptoms
is likely to improve HRQL measures. Future hydro-
cortisone trials should attempt to measure both depres-
sion and PTSD outcomes to further understand this
relationship.
There was no apparent difference in effectiveness
between interventions administered against placebo and
those compared to a different comparator. Only two trials
used a non-placebo comparator. Robert et al.47 used chloral
hydrate when investigating imipramine, while Nishi et al.39
used psychoeducation when investigating fish oil (224mg
DHA/22.4mg EPA). While both of these trials found no
significant difference between the two interventions, their
design does not allow conclusions to be drawn about actual
efficacy as the effect sizes will have been influenced by the
comparators’ effects on PTSD outcomes. Two other studies
compared an intervention against standard treatment;
Rosenberg et al.48 found no significant difference between
propranolol and standard treatment, while Schelling et al.41
found a significant reduction in PTSD symptoms in those
treated with hydrocortisone. The magnitude of this result
was similar to the other hydrocortisone trials but may have
been exaggerated due to the absence of a placebo
comparator group.
Many of the RCTs included in our meta-analyses were
small and the majority had areas of notable concern for
risk of bias; both of these applied to the three RCTs
evaluating hydrocortisone. No outcome received a
GRADE rating higher than low. This, combined with the
lack of studies for many outcomes, limits our confidence
in the best current evidence to determine the true effects
of early pharmacological intervention to prevent PTSD.
This meta-analysis does, however, compile a higher
quality of evidence than previously available.
Our work supports previous research investigating the
preventative effect of hydrocortisone, but there remains
insufficient evidence to recommend its administration
routinely. Even in the short term, hydrocortisone use can
produce numerous adverse effects, ranging from con-
gestive cardiac failure to insomnia. Of the studies we
considered, some reported no side effects43,44 while others
reported dizziness35 and an increased rate of infection/
septic shock, hyperglycaemia and hypernatraemia36,52. As
glucocorticoids have been widely used in medical practice
for the past 60 years we have good knowledge of the
adverse effects they cause, which may require further
medical intervention. While we have sufficient knowledge
of the adverse consequences of giving hydrocortisone to
people exposed to particular types of trauma, we must
further understand the potential benefits and risks in
other groups of trauma victims and determine individual
factors associated with outcome. Furthermore, severe
psychiatric side effects from corticosteroids occur in 6% of
patients, with mild to moderate effects occurring in 28%53.
The most common adverse effects are euphoria and
hypomania, although no psychiatric adverse effects were
documented in the hydrocortisone RCTs we examined.
While side effects are more likely to develop in those
requiring higher doses of corticosteroid, dosage does not
predict the onset, duration or severity of the adverse
reaction53. Nonetheless, this suggests caution should be
used when prescribing higher dosing regimes. Four RCTs
did not exclude patients with a previous psychiatric his-
tory, but very limited information was available about the
past psychiatric history of their participants. Schelling
et al.40, however, excluded patients with any psychiatric
co-morbidity, and Zohar et al.44, excluded patients with a
substance use disorder or history of brain trauma. Given
the known side effect profile of hydrocortisone, and the
reassuring results of studies which did not exclude those
with mental illness, we conclude that there is no absolute
contra-indication to hydrocortisone for those with pre-
existing mental disorder.
Thus, the potential benefit of the medication must be
balanced against the potential side effects and patients
may be reluctant to receive hydrocortisone in the absence
of symptoms. Some of the included studies had problems
recruiting participants35 and it is probable that a sig-
nificant proportion of people may not be particularly
willing to take medication to prevent PTSD. The reason
for reluctance to take medication (with 42.6% refusing
SSRI or placebo in one study42) is unclear and worthy of
further exploration. Reluctance to take medication should
not alter evidence-based recommendations to initiate safe
and effective pharmacotherapy to prevent PTSD, although
is very important with respect to considering imple-
mentation and should stimulate future research to con-
sider acceptability in more depth. It seems likely that an
optimal approach to offering preventative pharma-
cotherapy is to target those at highest risk of developing
PTSD (for example, those who experienced peritraumatic
dissociation) than offering intervention to all trauma-
exposed individuals. The evidence examined in this paper
suggests that certain agents may be more effective in
certain sub-groups of individuals, for example Zohar et al.
show the efficacy of escitalopram in victims of intentional
trauma, while van Zuiden et al. observe the beneficial
effects of oxytocin on trauma victims with high PTSD
symptom severity scores. While some of these trials used
post-hoc sub-group analyses, this was not the case for all
trials, with Delahanty et al.35, for example, including only
participants with high levels of peritraumatic dissociation.
Thus, it is possible that preventative pharmacotherapy
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will be most efficacious in those at highest risk of devel-
oping PTSD, with more severe initial symptom severity.
Similarly when examining dexamethasone, Kok et al.34
found a lower prevalence of PTSD and depressive symp-
toms in women in the intervention group, but were
unable to demonstrate lower PTSD/depression rates
overall. The trial was the largest included in the meta-
analysis, with 2458 participants, and used a stat dose of
intravenous dexamethasone (dissimilar to all hydro-
cortisone trials which used regular administration). The
study population was relatively healthy and only admitted
to an ITU overnight, leaving them at low risk of devel-
oping PTSD compared to other trials and possibly
explaining the failure of dexamethasone to prevent PTSD
in the population as a whole (but preventing PTSD in
women, a higher risk group). Further research should
build on this by clarifying which sub-groups best respond
to pharmacological prevention.
We conclude that in individuals with no contra-
indications to its prescription, hydrocortisone could be
considered as a preventative intervention for people
with severe physical illness or injury, shortly after a
traumatic event. While there are general indications that
hydrocortisone may be effective, questions remain
regarding the sub-groups most likely to benefit and so
more research is needed using larger, high quality RCTs
to establish the most efficacious use of hydrocortisone
in different populations and optimal dosing, dosing
window and route. Future research should also clarify
other pertinent questions, for instance it is possible that
hydrocortisone may impede declarative memory retrie-
val54, which could hinder the recall of testimony
required for trauma victims to secure convictions
against their perpetrators. Conversely, it is also possible
that over-consolidation, or shifts in the degree of con-
textualisation in consolidated memory in PTSD forma-
tion may affect accurate memory recall with similar
implications. In addition, further work is required to
consider other agents with potential such as oxytocin
and opioids, and to develop novel agents informed by
our improving neurobiological understanding of PTSD
and its development.
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